- Home
- MAIA
as 04-22-2025 4:00pm EST
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | CHICAGO |
| Market Cap: | 46.7M | IPO Year: | 2022 |
| Target Price: | N/A | AVG Volume (30 days): | 79.7K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.05 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.40 - $5.99 | Next Earning Date: | 05-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of MAIA Biotechnology Inc. (MAIA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Smith Stan | MAIA | Director | Mar 3 '25 | Buy | $1.50 | 25,000 | $37,500.00 | 1,205,060 | |
| Guerrero Ramiro | MAIA | Director | Mar 3 '25 | Buy | $1.50 | 33,333 | $49,999.50 | 568,218 | |
| Smith Stan | MAIA | Director | Feb 24 '25 | Buy | $1.50 | 100,000 | $150,000.00 | 1,205,060 | |
| Guerrero Ramiro | MAIA | Director | Feb 24 '25 | Buy | $1.50 | 73,333 | $109,999.50 | 568,218 |
Latest MAIA Biotechnology Inc. News
MAIA Breaking Stock News: Dive into MAIA Ticker-Specific Updates for Smart Investing
Business Wire
22 days ago
MAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to Shareholders
Insider Monkey
a month ago
Is MAIA Biotechnology, Inc. (MAIA)he Cheapest Stock Insiders Are Buying In March?
Zacks
a month ago
MAIA Biotechnology, Inc. (MAIA) Upgraded to Buy: Here's What You Should Know
Business Wire
a month ago
MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025
Business Wire
a month ago
MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug
Business Wire
a month ago
MAIA Biotechnology Receives USAN Council Approval for "Ateganosine" as Nonproprietary Name for Anticancer Agent THIO
Business Wire
2 months ago
MAIA Biotechnology to Initiate Phase 3 Pivotal Trial of THIO Sequenced with Checkpoint Inhibitor Compared with Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer Patients
Business Wire
2 months ago
MAIA Biotechnology Announces Design for Expansion of THIO-101 Phase 2 Trial in Advanced Non-Small Cell Lung Cancer
Compare MAIA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MAIA MAIA Biotechnology Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.